BioLineRx Ltd. (BLRX)
NASDAQ: BLRX · Real-Time Price · USD
2.630
+0.396 (17.73%)
At close: Apr 28, 2026, 4:00 PM EDT
2.546
-0.084 (-3.21%)
After-hours: Apr 28, 2026, 7:59 PM EDT
BioLineRx Revenue
In the year 2025, BioLineRx had annual revenue of $1.18M, down -95.92%. BioLineRx had revenue of $194.00K in the quarter ending December 31, 2025, a decrease of -98.35%.
Revenue (ttm)
$1.18M
Revenue Growth
-95.92%
P/S Ratio
8.91
Revenue / Employee
$49,167
Employees
24
Market Cap
10.52M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionBLRX News
- 15 hours ago - BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) - PRNewsWire
- 20 days ago - BioLineRx (BLRX) Partners in Groundbreaking Glioblastoma Trial - GuruFocus
- 20 days ago - Hemispherian Initiates Phase 1/2a Clinical Trial of GLIX1 in Glioblastoma - Business Wire
- 4 weeks ago - BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) - PRNewsWire
- 5 weeks ago - BioLineRx Earnings Call Transcript: Q4 2025 - Transcripts
- 5 weeks ago - Earnings Scheduled For March 23, 2026 - Benzinga
- 5 weeks ago - BioLineRx Reports 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 5 weeks ago - BioLineRx (BLRX) and Others Set to Announce Earnings - GuruFocus